Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 13,345

Document Document Title
WO/2018/164191A1
The present invention provides a substituted pyrrolidine compound having orexin receptor type 2 agonist activity. A compound represented by the formula (in the formula, each symbol is as described in the specification) or a salt thereof ...  
WO/2018/165071A1
The present disclosure relates to solid state forms of Midostaurin, processes for preparation thereof, pharmaceutical compositions thereof, and use thereof in the treatment of Acute Myelogenous Leukemia (AML) and Aggressive Systemic Mast...  
WO/2018/162443A1
The present invention relates to tricyclic inhibitors of beta-secretase having the structure shown in Formula (I) and (II) and the tautomers and the stereoisomeric forms thereof, wherein the radicals are as defined in the specification. ...  
WO/2018/161960A1
10-oxo-6,1-dihydrobenzo[e]pyrido[1,2-c][1,3]oxazine-9-carbox ylic acid derivatives of formula (I) as hepatitis B surface antigen inhibitors or pharmaceutically acceptable salts thereof, and uses of a compound of formula (I) or pharmaceut...  
WO/2018/160892A1
Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V,...  
WO/2018/158646A1
The present invention relates to a process for the preparation of crystalline Form GR of Rifaximin (I). The invention also relates to crystalline Form GR of Rifaximin obtained by the process of the present invention, the said Form GR bei...  
WO/2018/160003A1
The present specification relates to a heterocyclic compound of chemical formula 1 and an organic light-emitting device comprising same.  
WO/2018/155275A1
Provided is an oxygen-bridged triphenylamine compound that is suitable for a light-emitting material of an organic electroluminescent element. The compound is represented by formula (1) [wherein ring A, ring B and ring C independently re...  
WO/2018/153507A1
Compounds of formula (I), wherein R', R'', R, X, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.  
WO/2018/149608A1
The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir s...  
WO/2018/148204A1
Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2018/141854A1
The present invention provides piperazine derivatives exhibiting high affinity to the stem region (viral membrane proximal part) of influenza hemagglutinin as determined through competition binding and high virus neutralization activity ...  
WO/2018/144605A1
The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.  
WO/2018/143638A1
The present invention relates to a 4'-phosphopantetheinyl transferase enzyme inhibitor derived from Mycobacterium tuberculosis, and a pharmaceutical composition for preventing or treating tuberculosis, containing the same as an active in...  
WO/2018/144789A1
The present disclosure provides fused 1,4-diazepines represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, E, R1, R2, R3, R4, R5, and Ar are as defined as set forth in the specification. T...  
WO/2018/140554A1
The present disclosure relates to methods and compositions for treating cancer with a diaryl macrocycle in combination with at least one other cancer therapeutic, such as an EGFR inhibitor.  
WO/2018/137679A1
The present application disclosed a process for the preparing (10R) -7- (2-aminoacetyl) amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4- (metheno) pyrazolo [4, 3-h] [2, 5, 11] -benzoxadiazacyclotetradecine-3-...  
WO/2018/138088A1
The present invention relates to certain bicyclic bis-heteroaryl compounds of Formula (I), pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protei...  
WO/2018/138739A1
The present invention provides novel heterocyclic compounds of Formula I wherein A, B, E, ring Z, Y, L, ring X, D, m, n, R7 and R8 are as defined in the specification as estrogen receptor antagonists/degraders. The compound of Formula I ...  
WO/2018/134698A1
The present invention provides, in part, heterocyclic spiro compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing su...  
WO/2018/136890A1
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLR...  
WO/2018/136265A1
The present disclosure is directed to inhibitors of SHP2 and their use in the treatment of disease. Also disclosed are pharmaceutical compositions comprising the same.  
WO/2018/129411A1
Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases o...  
WO/2018/128407A1
The present invention relates to a novel quinolinone derivative compound which is efficacious for preventing or treating an allergic disease such as asthma or atopy by controlling intracellular signaling via SLP and IL-33. The quinolinon...  
WO/2018/124060A1
Provided is a compound represented by general formula (1) or a pharmaceutically-acceptable salt thereof. [In formula (1), R1 and R2 may be the same or different from each other, and each represents a hydrogen atom, a halogen atom, a hydr...  
WO/2018/125880A1
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use and production.  
WO/2018/119362A3
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/119449A1
The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formul...  
WO/2018/119266A1
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders...  
WO/2018/115111A1
The present invention relates to a method for the manufacture of 2-(3-(alkyl or alkenyl)morpholino)-ethan-1-ols by reduction of 8a-(alkyl and alkenyl)hexahydrooxazolo[2,3-c][1,4]oxazines encompassing a process for producing 2-(3-(4-propy...  
WO/2018/113538A1
The present invention relates to an organic compound with homobenzene as a core and the use thereof in an OLED device. The compound of the present invention has a higher glass transition temperature, a higher molecular heat stability, ap...  
WO/2018/118781A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, wherein R1, A, and J are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...  
WO/2018/119362A2
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).  
WO/2018/118842A1
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of...  
WO/2018/118551A1
This disclosure relates to the field of molecules having pesticidal utility against pests in phyla Nematoda, Arthropoda, and/or Mollusca, processes to produce such molecules and intermediates used in such processes, compositions containi...  
WO/2018/116072A1
The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compo...  
WO/2018/117493A1
The present invention relates to a novel compound and an organic electroluminescent device comprising the same. According to the present invention, the compound is used in an organic material layer, preferably in a light-emitting layer, ...  
WO/2018/119444A1
The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formul...  
WO/2018/111707A1
A compound, as defined herein, or pharmaceutical composition containing the compound, for use in treating IDH1 or IDH2 mutant cancer and having the structure: (I).  
WO/2018/109643A1
The present invention relates to bisaryl heterocycle compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula...  
WO/2018/109204A1
Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound 18, having the structure (I).  
WO/2018/112084A1
The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula (I): (Formula (I)) wherein variables X, Y, R2, R3, R4, R5, R6, and n of For...  
WO/2018/109496A2
The present invention relates to a process for the preparation compounds of Formula (I): Formula (I) wherein X, Z, Q, Ar, R1, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation o...  
WO/2018/109649A1
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and...  
WO/2018/109786A1
The present invention provides novel polymorphs of (3S,11aR)-N-[(2,4-difluorophenyl) methyl]-6- hydroxy-3-methyl-5, 7-dioxo-2, 3,5,7, 11, 11a-hexahydro[1, 3]oxazolo[3, 2-a]pyrido[1, 2-d]pyrazine-8-carboxamide including sodium and potassi...  
WO/2018/109097A1
The invention provides novel compounds having RIP1 kinase inhibitory activity, pharmaceutical compositions including the compounds and methods of using the compounds.  
WO/2018/112094A1
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...  
WO/2018/109496A3
The present invention relates to a process for alpha-arylation of heterocyclic urea derivatives by aryl transfer rearrangement for the preparation compounds of Formula (I): wherein X, Z, Q, Ar, R1, R2, R3 and R4 are each as defined herein.  
WO/2018/109646A1
The present invention relates to a compound which is (R)-3-(1,4- dimethyl-1 H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3- dihydropyrido[2,3-f][l,4]oxazepin-4(5H)-yl)methyl)-4-methylp henyl) propanoic acid (I), or a pharmaceutica...  
WO/2018/109647A1
The present invention relates to bisaryl amide analogs, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to bisaryl heterocycles of Formula (I).  

Matches 1 - 50 out of 13,345